Milken Institute Launches COVID-19 Treatment and Vaccine Tracker

Milken Institute Launches COVID-19 Treatment and Vaccine Tracker

While the world eagerly waits for any sign of a cure to COVID-19, the Santa Monica-based Milken Institute has launched a publicly accessible spreadsheet to help the public and policymakers track progress of possible treatments and vaccines. It is developed and maintained by FasterCures, a division of Milken, along with an advisory council of former FDA chiefs, industry leaders, and a Nobel Laureate researcher.


"As we're following what's going on in research and development, there was so much out there that we felt like it would be a public service for interested stakeholders to pull it all together," Brenda Huneycutt, Director of FasterCures, told dot.LA.

The treatments and vaccines aren't listed in any particular order. FasterCures did not want to be put in the position of ranking which treatments show the most potential or endorsing certain approaches.

"That's for the experts," said Huneycutt. "We can't say which ones are most promising because things are changing so quickly."

This week, the first patients in a clinical trial for a potential COVID-19 vaccine were given shots at Kaiser Permanente Research Institute in Seattle. Experts have said a treatment will likely be developed before a vaccine, which could take up to a year to get to the public, according to the U.S. FDA Commissioner Stephen Hahn.

FasterCures will continue updating the list, which will grow – hopefully sooner rather than later – to include FDA-approved remedies.

"We seek to accelerate efforts to find new treatments or vaccines, amplify what's working, hold the system and its players accountable, and expand the global discussion about how to create durable, long term solutions," Esther Krofah, executive director of FasterCures, said in a statement. "COVID-19 is putting that approach to the test. We hope to be a resource promoting effective approaches and strategies."

https://twitter.com/thebenbergman
ben@dot.la

Subscribe to our newsletter to catch every headline.

RELATEDTRENDING